U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Cutaneous anergy

MedGen UID:
344575
Concept ID:
C1855781
Finding
Synonyms: Absence of delayed hypersensitivity skin test; Lack of delayed skin hypersensitivity reaction
 
HPO: HP:0002965

Definition

Inability to react to a delayed hypersensitivity skin test. [from HPO]

Conditions with this feature

T-B+ severe combined immunodeficiency due to JAK3 deficiency
MedGen UID:
331474
Concept ID:
C1833275
Disease or Syndrome
JAK3-deficient severe combined immunodeficiency (SCID) is an inherited disorder of the immune system. Individuals with JAK3-deficient SCID lack the necessary immune cells to fight off certain bacteria, viruses, and fungi. They are prone to repeated and persistent infections that can be very serious or life-threatening. Often the organisms that cause infection in people with JAK3-deficient SCID are described as opportunistic because they ordinarily do not cause illness in healthy people. Affected infants typically develop chronic diarrhea, a fungal infection in the mouth called oral thrush, pneumonia, and skin rashes. Persistent illness also causes affected individuals to grow more slowly than other children. Without treatment, people with JAK3-deficient SCID usually live only into early childhood.
Chronic mucocutaneous candidiasis due to monocyte chemotactic disorder
MedGen UID:
343238
Concept ID:
C1854982
Disease or Syndrome
Vici syndrome
MedGen UID:
340962
Concept ID:
C1855772
Disease or Syndrome
With the current widespread use of multigene panels and comprehensive genomic testing, it has become apparent that the phenotypic spectrum of EPG5-related disorder represents a continuum. At the most severe end of the spectrum is classic Vici syndrome (defined as a neurodevelopmental disorder with multisystem involvement characterized by the combination of agenesis of the corpus callosum, cataracts, hypopigmentation, cardiomyopathy, combined immunodeficiency, microcephaly, and failure to thrive); at the milder end of the spectrum are attenuated neurodevelopmental phenotypes with variable multisystem involvement. Median survival in classic Vici syndrome appears to be 24 months, with only 10% of children surviving longer than age five years; the most common causes of death are respiratory infections as a result of primary immunodeficiency and/or cardiac insufficiency resulting from progressive cardiac failure. No data are available on life span in individuals at the milder end of the spectrum.
Bare lymphocyte syndrome type 2, complementation group A
MedGen UID:
395288
Concept ID:
C1859534
Disease or Syndrome
Bare lymphocyte syndrome type II (BLS II) is an inherited disorder of the immune system categorized as a form of combined immunodeficiency (CID). People with BLS II lack virtually all immune protection from bacteria, viruses, and fungi. They are prone to repeated and persistent infections that can be very serious or life-threatening. These infections are often caused by "opportunistic" organisms that ordinarily do not cause illness in people with a normal immune system.\n\nBLS II is typically diagnosed in the first year of life. Most affected infants have persistent infections in the respiratory, gastrointestinal, and urinary tracts. Because of the infections, affected infants have difficulty absorbing nutrients (malabsorption), and they grow more slowly than their peers. Eventually, the persistent infections lead to organ failure. Without treatment, individuals with BLS II usually do not survive past early childhood.\n\nIn people with BLS II, infection-fighting white blood cells (lymphocytes) are missing specialized proteins on their surface called major histocompatibility complex (MHC) class II proteins, which is where the condition got its name. Because BLS II is the most common and best studied form of a group of related conditions, it is often referred to as simply bare lymphocyte syndrome (BLS).
Splenomegaly syndrome with splenic Germinal center hypoplasia and reduced circulating T helper cells
MedGen UID:
357126
Concept ID:
C1866744
Disease or Syndrome
Candidiasis, familial, 1
MedGen UID:
414015
Concept ID:
C2751429
Disease or Syndrome
Chronic mucocutaneous candidiasis (CMC) includes a group of rare disorders with altered immune responses, selective against Candida, characterized by persistent and/or recurrent infections of the skin, nails, and mucous membranes, caused by organisms of the genus Candida, mainly Candida albicans (Zuccarello et al., 2002). Isolated familial chronic mucocutaneous candidiasis is distinct from candidiasis with endocrinopathy (240300). In myeloperoxidase deficiency (254600), susceptibility to candidiasis may be increased. Genetic Heterogeneity of Candidiasis Familial candidiasis-1 (CANDF1) maps to chromosome 2p. CANDF2 (212050) is caused by mutation in the CARD9 gene (607212) on chromosome 9q34.3. CANDF3 (607644), a form restricted to nails of the hands and feet, maps to chromosome 11. CANDF4 (613108) is caused by mutation in the CLEC7A gene (606264) on chromosome 12p13. CANDF6 (613956) is caused by mutation in the IL17F gene (606496) on chromosome 6p12. CANDF7 (614162) is caused by mutation in the STAT1 gene (600555) on chromosome 2q32. CANDF8 (615527) is caused by mutation in the TRAF3IP2 gene (607043) on chromosome 6q21. CANDF9 (616445) is caused by mutation in the IL17RC gene (610925) on chromosome 3p25. A form of familial candidiasis, previously thought to be isolated and designated CANDF5, has been found to be part of a primary immune deficiency (IMD51; 613953) that includes Staphylococcal skin infections and increased susceptibility to chronic bacterial respiratory infections.

Professional guidelines

Recent clinical studies

Etiology

Harris TG, Burk RD, Xue X, Anastos K, Minkoff H, Massad LS, Young MA, Levine AM, Gange SJ, Watts DH, Palefsky JM, Strickler HD
AIDS 2007 Sep 12;21(14):1933-41. doi: 10.1097/QAD.0b013e3282c3a945. PMID: 17721101
Ohrui T
Tohoku J Exp Med 2005 Sep;207(1):3-12. doi: 10.1620/tjem.207.3. PMID: 16082150
Lloyd AR, Wakefield D, Hickie I
Ciba Found Symp 1993;173:176-87; discussion 187-92. doi: 10.1002/9780470514382.ch11. PMID: 8491097
Soave R, Danner RL, Honig CL, Ma P, Hart CC, Nash T, Roberts RB
Ann Intern Med 1984 Apr;100(4):504-11. doi: 10.7326/0003-4819-100-4-504. PMID: 6703542
Kataria YP, LoBuglio AF, Bromberg PA, Hurtubise PE
Ann N Y Acad Sci 1976;278:69-79. doi: 10.1111/j.1749-6632.1976.tb47017.x. PMID: 786127

Diagnosis

Belfer MH, Stevens RW
Am Fam Physician 1998 Dec;58(9):2041-50, 2055-6. PMID: 9861878
Miyata M, Takase Y, Kobayashi H, Kokubun M, Yoshimura A, Katsuura Y, Nishimaki T, Kasukawa R
Intern Med 1998 Feb;37(2):174-8. doi: 10.2169/internalmedicine.37.174. PMID: 9550600
Kerdel FA, Moschella SL
J Am Acad Dermatol 1984 Jul;11(1):1-19. doi: 10.1016/s0190-9622(84)70133-2. PMID: 6376553
Lerner CW, Tapper ML
Medicine (Baltimore) 1984 May;63(3):155-64. doi: 10.1097/00005792-198405000-00002. PMID: 6325849
Goldblum SE, Reed WP
Ann Intern Med 1980 Oct;93(4):597-613. doi: 10.7326/0003-4819-93-4-597. PMID: 7001976

Therapy

Ohrui T
Tohoku J Exp Med 2005 Sep;207(1):3-12. doi: 10.1620/tjem.207.3. PMID: 16082150
MMWR Recomm Rep 1997 Sep 5;46(RR-15):1-10. PMID: 9332982
Pamphilon DH, Alnaqdy AA, Wallington TB
Immunol Today 1991 Apr;12(4):119-23. doi: 10.1016/0167-5699(91)90095-B. PMID: 2059312
Kerdel FA, Moschella SL
J Am Acad Dermatol 1984 Jul;11(1):1-19. doi: 10.1016/s0190-9622(84)70133-2. PMID: 6376553
Goldblum SE, Reed WP
Ann Intern Med 1980 Oct;93(4):597-613. doi: 10.7326/0003-4819-93-4-597. PMID: 7001976

Prognosis

Harris TG, Burk RD, Xue X, Anastos K, Minkoff H, Massad LS, Young MA, Levine AM, Gange SJ, Watts DH, Palefsky JM, Strickler HD
AIDS 2007 Sep 12;21(14):1933-41. doi: 10.1097/QAD.0b013e3282c3a945. PMID: 17721101
Shankar MS, Aravindan AN, Sohal PM, Kohli HS, Sud K, Gupta KL, Sakhuja V, Jha V
Nephrol Dial Transplant 2005 Dec;20(12):2720-4. Epub 2005 Sep 27 doi: 10.1093/ndt/gfi141. PMID: 16188895
Soave R, Danner RL, Honig CL, Ma P, Hart CC, Nash T, Roberts RB
Ann Intern Med 1984 Apr;100(4):504-11. doi: 10.7326/0003-4819-100-4-504. PMID: 6703542
Kerdel FA, Moschella SL
J Am Acad Dermatol 1984 Jul;11(1):1-19. doi: 10.1016/s0190-9622(84)70133-2. PMID: 6376553
Eilber FR, Morton DL
Surg Forum 1969;20:116-7. PMID: 5383024

Clinical prediction guides

Shankar MS, Aravindan AN, Sohal PM, Kohli HS, Sud K, Gupta KL, Sakhuja V, Jha V
Nephrol Dial Transplant 2005 Dec;20(12):2720-4. Epub 2005 Sep 27 doi: 10.1093/ndt/gfi141. PMID: 16188895
Bennett BK, Hickie IB, Vollmer-Conna US, Quigley B, Brennan CM, Wakefield D, Douglas MP, Hansen GR, Tahmindjis AJ, Lloyd AR
Aust N Z J Psychiatry 1998 Apr;32(2):180-6. doi: 10.3109/00048679809062727. PMID: 9588296
Graham NM, Galai N, Nelson KE, Astemborski J, Bonds M, Rizzo RT, Sheeley L, Vlahov D
Arch Intern Med 1996 Apr 22;156(8):889-94. PMID: 8774208
Pamphilon DH, Alnaqdy AA, Wallington TB
Immunol Today 1991 Apr;12(4):119-23. doi: 10.1016/0167-5699(91)90095-B. PMID: 2059312
Huberman M, Fossieck BE Jr, Bunn PA Jr, Cohen MH, Ihde DC, Minna JD
Am J Med 1980 Feb;68(2):214-8. doi: 10.1016/0002-9343(80)90356-3. PMID: 6243858

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...